png440x100.png){kind=logo}
REIGNITE
Real-world Evidence of IgA Nephropathy to Investigate Therapeutic Effectiveness
WHY REIGNITE?
Approximately half of patients with IgA nephropathy progress to kidney failure.
Much of the existing evidence derives from historical cohorts that predate current therapies, which limits both precision and generalizability. The recent expansion of treatment options for IgAN has outpaced the real-world evidence describing how these agents are used and how patients respond.
REIGNITE assembles contemporary, longitudinal data from a broad range of nephrology centers to characterize current practice and outcomes at a scale individual centers cannot reach.
Study Objectives
REIGNITE is designed to examine, in real-world IgAN populations:
-
Disease course: Changes in kidney function over time
-
Treatment use: How established and newer agents are used in practice
-
Sequencing and combination: The order in which therapies are initiated, and how they are combined
-
Predictors of treatment response: Characteristics associated with differences in response and outcome
-
Outcomes of interest: Cardiovascular events, infection, malignancy, pregnancy, and treatment-related effects
WHAT YOUR SITE GAINS
What your participation includes.
01
Financial Support
A start-up payment and per-patient reimbursement recognizing your team's recruitment and data-entry effort, set at fair market value.
04
Authorship
Co-authorship on the joint publication, based on contribution and consistent with academic authorship standards.
02
Free RADIANT training
Enrollment in GlomCon's 9-month mentored clinical-research program (normally tuition-based).
05
Data ownership
Your site retains its own patient records and clinical data for independent research without GlomCon's permission.
03
Network Membership
Access to the National Rare Kidney Disease Network, including Designated Clinical Trial Site recognition, the Research Shark Tank, members-only seed funding, and clinic-development support.
HOW IT WORKS
Designed to fit your clinic.
GlomCon coordinates protocol development, regulatory templates, site training, data cleaning, analysis, and manuscript preparation.
Participating sites identify eligible patients and abstract de-identified data into the study platform.
No study visits, interventions, or change to care
De-identified data only; your site holds the linking key
Waiver of consent; IRB templates provided
Central IRB available for faster start-up
Data entry at least every six months
Secure EDC · 21 CFR Part 11 · SOC 2 · ISO 27001
Be part of a research network.
Participating in REIGNITE connects your center to the National Rare Kidney Disease Network and to GlomCon's research, education, and training activities.
Acknowledgement
The REIGNITE Study is funded by:
